新華製藥(000756.SZ):8名董事、高管共完成減持28.19萬股A股 財務負責人侯寧1股未減、提前終止減持
格隆匯7月29日丨新華製藥(000756.SZ)公佈,公司近日收到董事長張代銘、董事徐列、副總經理王小龍、副總經理杜德清、董事、副總經理賀同慶、副總經理魏長生、副總經理徐文輝及董事會祕書曹長求出具的《減持計劃實施完成吿知函》及財務負責人侯寧出具的《關於提前終止股份減持計劃的吿知函》。
截至2022年7月29日,張代銘、徐列、王小龍、杜德清、賀同慶、魏長生、徐文輝及曹長求披露的減持計劃實施已完成,上述人員在減持期間內通過集中競價方式合計減持公司股份28.19萬股A股。
另外,侯寧基於自身情況,決定提前終止此次減持計劃,其尚未通過任何方式減持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.